Equol

2 papers2 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Japan Society for the Promotion of Science and 3 more

Humans1

Associations

Low physical activity

downin humans1OR 0.6

1 study

Equol lowers the risk of low physical activity in humans (OR 0.60, 95% CI 0.41–0.88).
“Among the frailty components, low physical activity was associated with equol production (OR=0.60; 95% CI, 0.41-0.88).”
Humansadjusted for age and sexn = 651
Association of Urinary Equol Concentration with Frailty in Community-Dwelling Older Adults: The Itabashi Longitudinal Study on Aging
Clinical interventions in aging21 Jan 2026

Frailty or prefrailty

downin humans1OR 0.71

1 study

Equol lowers the risk of frailty or prefrailty in humans (OR 0.71, 95% CI 0.51–0.97).
“Equol producers had a significantly lower odds ratio (OR) for frailty or prefrailty (OR=0.71; 95% CI, 0.51-0.97) compared to non-producers.”
Humansadjusted for age and sexn = 651
Association of Urinary Equol Concentration with Frailty in Community-Dwelling Older Adults: The Itabashi Longitudinal Study on Aging
Clinical interventions in aging21 Jan 2026

Funding

5 grants since 2023

National Institute on AgingUS$12.6mNational Heart, Lung, and Blood InstituteUS$2.4mNational Institute of Arthritis and Musculoskeletal and Skin DiseasesUS$417.9k